{"nctId":"NCT00387088","briefTitle":"Tiotropium / Respimat One Year Study in COPD.","startDateStruct":{"date":"2006-09"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":3991,"armGroups":[{"label":"Tiotropium","type":"OTHER","interventionNames":["Drug: Tiotropium"]},{"label":"Placebo","type":"OTHER","interventionNames":["Device: Respimat"]}],"interventions":[{"name":"Respimat","otherNames":[]},{"name":"Tiotropium","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female\n2. At least 40 years old\n3. Smoker or ex-smoker\n4. Smoking history \\> 10 pack-years\n5. Forced Expiratory Volume in 1 Second (FEV1) \\< 60% predicted\n\nExclusion Criteria:\n\n1. Recent history of myocardial infarction, life-threatening cardiac arrhythmia or hospitalisation for cardiac failure\n2. History of asthma or allergic conditions.\n3. Malignancy requiring treatment within past 5 years\n4. Life-threatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis\n5. Known active tuberculosis\n6. Known hypersensitivity to anticholinergic drugs.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 337","description":"Trough FEV1 is defined as the FEV1 measured at the -10 min time point at the end of the dosing interval (24 h post drug administration).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.119","spread":"0.007"},{"groupId":"OG001","value":"0.018","spread":"0.007"}]}]}]},{"type":"PRIMARY","title":"Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation","description":"Time to first COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 29","description":"Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.005"},{"groupId":"OG001","value":"0.017","spread":"0.005"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 169","description":"Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.121","spread":"0.006"},{"groupId":"OG001","value":"0.018","spread":"0.006"}]}]}]},{"type":"SECONDARY","title":"Number of COPD Exacerbations Per Patient - Exposure Adjusted","description":"Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. number of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Number of COPD Exacerbations Per Patient - na誰ve Estimate","description":"Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. na誰ve estimate)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With at Least One COPD Exacerbation","description":"Number of patients with at least one COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"685","spread":null},{"groupId":"OG001","value":"842","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Hospitalisation for COPD Exacerbation","description":"Time to first hospitalisation for COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Hospitalisations for COPD Exacerbations Per Patient - Exposure Adjusted","description":"Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. no. of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Hospitalisations for COPD Exacerbations Per Patient - na誰ve Estimate","description":"Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. na誰ve estimate)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With at Least One Hospitalisation for a COPD Exacerbation","description":"Number of patients with at least one hospitalisation for a COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"198","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 337","description":"The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.726","spread":"0.372"},{"groupId":"OG001","value":"-1.787","spread":"0.374"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 169","description":"The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.764","spread":"0.348"},{"groupId":"OG001","value":"-2.568","spread":"0.35"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 337","description":"The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.260","spread":"0.546"},{"groupId":"OG001","value":"-3.307","spread":"0.548"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.196","spread":"0.456"},{"groupId":"OG001","value":"-0.226","spread":"0.460"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.873","spread":"0.409"},{"groupId":"OG001","value":"-2.038","spread":"0.412"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 169","description":"The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.555","spread":"0.530"},{"groupId":"OG001","value":"-3.268","spread":"0.532"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.573","spread":"0.432"},{"groupId":"OG001","value":"-1.218","spread":"0.435"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.917","spread":"0.390"},{"groupId":"OG001","value":"-2.935","spread":"0.392"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 29","description":"Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.176","spread":"0.009"},{"groupId":"OG001","value":"0.025","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 169","description":"Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.179","spread":"0.010"},{"groupId":"OG001","value":"0.019","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 337","description":"Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.168","spread":"0.011"},{"groupId":"OG001","value":"-0.001","spread":"0.011"}]}]}]},{"type":"SECONDARY","title":"Marked Changes From Baseline in Vital Signs at End of Treatment","description":"Marked changes from baseline in vital signs (diastolic and systolic blood pressure (DBP and SBP) and pulse rate (PR)) at end of treatment.\n\nSBP - Increase means SBP \\>150 mmHg and an increase above baseline of \\>25 mmHg. SBP - Decrease means SBP \\<100 mmHg and a decrease below baseline of \\>10 mmHg.\n\nDBP - Increase means DBP \\>90 mmHg and an increase above baseline of \\>10 mmHg. DBP - Decrease means DBP \\<60 mmHg and a decrease below baseline of \\>10 mmHg.\n\nPR - Increase means PR \\>100 bpm and an increase above baseline of \\>10 bpm. PR - Decrease means PR \\<60 bpm and a decrease below baseline of \\>10 bpm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinically Relevant Findings in Physical Examination and ECG","description":"Clinically relevant findings in Physical Examination and ECG at end of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1723","spread":null},{"groupId":"OG001","value":"1733","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null},{"groupId":"OG001","value":"215","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1674","spread":null},{"groupId":"OG001","value":"1677","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"241","spread":null},{"groupId":"OG001","value":"249","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":342,"n":1952},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Dyspnoea","Cough","Upper respiratory tract infection"]}}}